



Supplementary Figure 1. Risk of alcoholic, non-alcoholic and hepatitis C cirrhosis associated with PNPLA3 I48M, TM6SF2 E40K and HSD17B13.<sup>1,7</sup> Valenti et al. reports results from a recessive model.

### References

1. Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. *Nat Genet.* 2015;47(12):1443-1448. doi:10.1038/ng.3417.
2. Speliotes EK, Butler JL, Palmer CD, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. *Hepatology.* 2010;52(3):904-912. doi:10.1002/hep.23768.
3. Valenti L, Rumi M, Galmozzi E, et al. Patatin-like phospholipase domain-containing 3 I48M polymorphism, steatosis, and liver damage in chronic hepatitis C. *Hepatology.* 2011;53(3):791-799. doi:10.1002/hep.24123.
4. Liu Y-L, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. *Nat Commun.* 2014;5(1):4309. doi:10.1038/ncomms5309.
5. Liu Z, Que S, Zhou L, et al. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. *Sci Rep.* 2017;7(1):9273. doi:10.1038/s41598-017-09548-9.
6. Abul-Husn NS, Cheng X, Li AH, et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. *N Engl J Med.* 2018;378(12):1096-1106. doi:10.1056/NEJMoa1712191.
7. About F, Abel L, Cobat A. HCV-Associated Liver Fibrosis and HSD17B13. *N Engl J Med.* 2018;379(19):1875-1876. doi:10.1056/NEJMc1804638.